ITI 214

Drug Profile

ITI 214

Alternative Names: IC-200214; ITI-214

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intra-Cellular Therapies
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Parkinson's disease
  • Phase I Cognition disorders

Most Recent Events

  • 01 Mar 2018 Intra-Cellular Therapies plans a phase I/II trial for Heart Failure in USA , (NCT03387215)
  • 01 Sep 2017 Phase-I/II clinical trials in Parkinson's disease in USA (PO) (NCT03257046)
  • 06 Mar 2017 ITI 214 is still in phase I trials for Cognition disorders in USA and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top